Avantor, Inc. (AVTR) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $99.50M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$648.80M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $128.80M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income $147.40M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Reported | (m) | $99.50M | (m) | (m) | (m) | $33.50M | $58.70M | $1.08B | (m) | $401.20M | $12.20M |
| 2025-09-30 | Reported | (m) | -$648.80M | (m) | (m) | (m) | $35.70M* | $207.40M* | $1.10B | (m) | $390.30M | $22.30M |
| 2025-06-30 | Reported | (m) | $128.80M | (m) | (m) | (m) | $29.60M* | $154.40M* | $1.13B | (m) | $425.30M | $17.00M |
| 2025-03-31 | Reported | (m) | $147.40M | (m) | (m) | (m) | $28.00M | $109.30M | $1.05B | (m) | $387.50M | $21.20M |
| 2024-09-30 | Reported | (m) | $124.60M | (m) | (m) | (m) | $40.80M* | $244.80M* | $1.15B | (m) | $439.80M | $16.70M |
| 2024-06-30 | Reported | (m) | $175.80M | (m) | (m) | (m) | $45.80M* | $281.10M* | $1.12B | (m) | $405.70M | $21.70M |
| 2024-03-31 | Reported | (m) | $146.30M | (m) | (m) | (m) | $34.70M | $141.60M | $1.11B | (m) | $424.20M | $20.20M |
| 2023-09-30 | Reported | (m) | $210.20M | (m) | (m) | (m) | $37.70M* | $230.70M* | $1.14B | (m) | $368.40M | $28.10M |
| 2023-06-30 | Reported | (m) | $71.70M | (m) | (m) | (m) | $30.10M* | $168.20M* | $1.15B | (m) | $357.50M | $6.00M |
| 2023-03-31 | Reported | (m) | $231.20M | (m) | (m) | (m) | $28.00M | $219.50M | $1.16B | (m) | $393.60M | $34.30M |
| 2022-09-30 | Reported | (m) | $275.80M | (m) | (m) | (m) | $39.00M* | $258.30M* | $1.21B | (m) | $374.90M | $41.30M |
| 2022-06-30 | Reported | (m) | $295.60M | (m) | (m) | (m) | $36.30M* | $227.50M* | $1.26B | (m) | $352.10M | $38.90M |
| 2022-03-31 | Reported | (m) | $307.00M | (m) | (m) | (m) | $24.50M | $152.20M | $1.26B | (m) | $382.90M | $51.40M |
| 2021-09-30 | Reported | (m) | $237.20M | (m) | (m) | (m) | $32.60M* | $261.90M* | $1.22B | (m) | $378.70M | $29.70M |
| 2021-06-30 | Reported | (m) | $254.70M | (m) | (m) | (m) | $23.40M* | $263.80M* | $1.23B | (m) | $371.80M | $57.30M |
| 2021-03-31 | Reported | (m) | $266.30M | (m) | (m) | (m) | $15.10M | $126.90M | $1.17B | (m) | $346.50M | $47.40M |
| 2020-09-30 | Reported | (m) | $177.20M | (m) | (m) | (m) | $15.30M* | $281.50M* | $1.10B | (m) | $329.20M | -$65.60M |
| 2020-06-30 | Reported | (m) | $166.60M | (m) | (m) | (m) | $13.50M* | $89.20M* | $988.10M | (m) | $324.00M | $18.50M |
| 2020-03-31 | Reported | (m) | $158.40M | (m) | (m) | (m) | $12.60M | $253.10M | $1.02B | (m) | $343.50M | $17.70M |
| 2019-09-30 | Reported | (m) | $143.20M | (m) | (m) | (m) | $13.10M* | $197.90M* | $1.03B | (m) | $330.80M | $15.20M |
| 2019-06-30 | Reported | (m) | $119.10M | (m) | (m) | (m) | $14.00M* | -$5.90M* | $1.04B | (m) | $372.00M | -$1.90M |
| 2019-03-31 | Reported | (m) | $137.60M | (m) | (m) | (m) | $12.40M | $75.00M | $1.00B | (m) | $337.60M | $10.10M |
| 2018-09-30 | Reported | (m) | $132.20M | (m) | (m) | (m) | $9.20M* | $108.20M* | $1.02B | (m) | $346.50M | -$33.40M |
| 2018-06-30 | Reported | (m) | $94.40M | (m) | (m) | (m) | (m) | (m) | $1.01B | (m) | $373.60M | $3.40M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$246.20M | (m) | (m) | (m) | $128.80M | $623.80M | $4.41B | (m) | $1.60B | $88.90M |
| 2024-12-31 | Reported | (m) | $1.08B | (m) | (m) | (m) | $148.80M | $840.80M | $4.50B | (m) | $1.64B | $142.40M |
| 2023-12-31 | Reported | (m) | $696.40M | (m) | (m) | (m) | $146.40M | $870.00M | $4.60B | (m) | $1.51B | $89.40M |
| 2022-12-31 | Reported | (m) | $1.13B | (m) | (m) | (m) | $133.40M | $843.60M | $4.91B | (m) | $1.47B | $164.60M |
| 2021-12-31 | Reported | (m) | $972.20M | (m) | (m) | (m) | $111.10M | $953.60M | $4.88B | (m) | $1.53B | $180.40M |
| 2020-12-31 | Reported | (m) | $706.80M | (m) | (m) | (m) | $61.60M | $929.80M | $4.31B | (m) | $1.37B | -$54.30M |
| 2019-12-31 | Reported | (m) | $551.80M | (m) | (m) | (m) | $51.60M | $354.00M | $4.12B | (m) | $1.37B | $2.80M |
| 2018-12-31 | Reported | (m) | $413.50M | (m) | (m) | (m) | $37.70M | $200.50M | $4.04B | (m) | $1.41B | -$26.90M |
| 2017-12-31 | Reported | (m) | -$210.40M | (m) | (m) | (m) | $25.20M | -$167.50M | $814.60M | (m) | $449.70M | -$314.90M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |